N-(1-methoxy)propyl thiourea | 66892-33-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫脲类
• 英文名称: N-(1-methoxy)propyl thiourea
• 英文别名: 3-methoxypropylthiourea
• CAS: 66892-33-9
• 化学式: C₅H₁₂N₂OS
• 分子量: 148.229
• InChiKey: FDWYDCXQLVOMPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  N-(1-methoxy)propyl thiourea 、 2-Bromo-1-[4-(2-propan-2-ylphenyl)sulfanyl-3-(trifluoromethyl)phenyl]ethanone 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 (4-(4-(2-Isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-thiazol-2-yl)-(3-methoxy-propyl)-amine
  参考文献：
  名称：

  Amino-substituted heterocycles as isosteres of trans-cinnamides: design and synthesis of heterocyclic biaryl sulfides as potent antagonists of LFA-1/ICAM-1 binding

  摘要：

  2-Amino-4-phenyl pyridine and, to a lesser extent, 4-amino-6-phenyl pyrimidine, were established as isosteres of transcinnamide moiety. Applying this isosterism to previously reported p-arylthio cinnamides resulted in the identification of 4-amino-6-(p-arylthio)phenyl-pyrimidines and 2-amino-4-(p-arylthio)phenyl-pyridines as potent antagonists of LFA-1/ICAM-1 binding. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.008
• 作为产物：
  描述：

  3-甲氧基丙基 在 氨 作用下， 生成 N-(1-methoxy)propyl thiourea
  参考文献：
  名称：

  取代5,5'-二苯基-2-硫代咪唑啉酮-4-酮作为CB1大麻素受体配体：合成和药理学评估。

  摘要：

  合成了一组30个取代的5,5'-二苯基-2-硫代氧杂咪唑啉-4-酮（硫代乙内酰脲）衍生物，并评估了它们对人CB（1）大麻素受体的亲和力。这些化合物衍生自先前描述的大麻素配体5,5'-二苯基咪唑烷-2,4-二酮（乙内酰脲）。用硫取代氧会导致亲和力增加，而[[35] S] GTPgammaS实验所确定的功能（即反向激动作用）仍然不受影响。最后，为了评估可能影响巯基乙内酰脲亲和力的分子参数，对代表性的巯基乙内酰脲和乙内酰脲衍生物进行了分子静电势以及亲脂性计算。总之，5,5'-双-（4-碘苯基）-3-丁基-2-硫代氧杂咪唑啉丁-4-酮（31）和3-烯丙基-5，

  DOI：

  10.1021/jm049263k

文献信息

• [EN] THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS<br/>[FR] DERIVES DE THIOXANTHINE UTILISES COMME INHIBITEURS DE LA MYELOPEROXYDASE
  申请人：ASTRAZENECA AB

  公开号：WO2003089430A1

  公开（公告）日：2003-10-30

  There is disclosed the use of a compound of formula (Ia) or (Ib)wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

  本文披露了化合物的使用，其化学式为(Ia)或(Ib)，其中R1、R2、R3、R4、X和Y如规范中所定义，以及其药用可接受的盐，在制备药物时用于治疗或预防通过抑制酶髓过氧化物酶（MPO）对疾病或情况有益的药物。本文披露了化学式(Ia)或(Ib)的某些新型化合物及其药用可接受的盐，以及其制备过程。化学式(Ia)和(Ib)的化合物是MPO抑制剂，因此在神经炎症性疾病的治疗或预防中特别有用。
• Thioxanthine derivatives as myeloperoxidase inhibitors
  申请人：Hanson Sverker

  公开号：US20050234036A1

  公开（公告）日：2005-10-20

  There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R 1 , R 2 , R 3 , R 4 , X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

  本文公开了化合物(Ia)或(Ib)的使用，其中R1、R2、R3、R4、X和Y如规范中所定义，并公开了其药学上可接受的盐，在制造药物方面，用于治疗或预防酶髓过氧化物酶(MPO)抑制有益的疾病或状况。公开了某些新颖的化合物(Ia)或(Ib)及其药学上可接受的盐，以及它们的制备方法。化合物(Ia)和(Ib)是MPO抑制剂，因此在治疗或预防神经炎性疾病方面特别有用。
• Thioxanthine Derivatives as Myeloperoxidase Inhibitors
  申请人：Hanson Sverker

  公开号：US20080293748A1

  公开（公告）日：2008-11-27

  There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R 1 , R 2 , R 3 , R 4 , X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

  本发明公开了使用式(Ia)或(Ib)的化合物及其药学上可接受的盐在制备药物时的应用，其中R1、R2、R3、R4、X和Y如规范所定义，用于治疗或预防抑制酶髓过氧化物酶(MPO)对于疾病或病情的益处。公开了某些新颖的化合物(Ia)或(Ib)及其药学上可接受的盐，以及其制备方法。式(Ia)和(Ib)的化合物是MPO抑制剂，因此在治疗或预防神经炎症性疾病方面特别有用。
• Amino-substituted heterocycles as isosteres of trans-cinnamides: design and synthesis of heterocyclic biaryl sulfides as potent antagonists of LFA-1/ICAM-1 binding
  作者：Gary T. Wang、Sheldon Wang、Robert Gentles、Thomas Sowin、Sandra Leitza、Edward B. Reilly、Thomas W. von Geldern

  DOI：10.1016/j.bmcl.2004.10.008

  日期：2005.1

  2-Amino-4-phenyl pyridine and, to a lesser extent, 4-amino-6-phenyl pyrimidine, were established as isosteres of transcinnamide moiety. Applying this isosterism to previously reported p-arylthio cinnamides resulted in the identification of 4-amino-6-(p-arylthio)phenyl-pyrimidines and 2-amino-4-(p-arylthio)phenyl-pyridines as potent antagonists of LFA-1/ICAM-1 binding. (C) 2004 Elsevier Ltd. All rights reserved.
• Substituted 5,5‘-Diphenyl-2-thioxoimidazolidin-4-one as CB₁ Cannabinoid Receptor Ligands:  Synthesis and Pharmacological Evaluation
  作者：Giulio G. Muccioli、Diana Martin、Gerhard K. E. Scriba、Wolfgang Poppitz、Jacques H. Poupaert、Johan Wouters、Didier M. Lambert

  DOI：10.1021/jm049263k

  日期：2005.4.1

  the human CB(1) cannabinoid receptor has been evaluated. These compounds are derived from the previously described cannabinoid ligands 5,5'-diphenylimidazolidine-2,4-dione (hydantoins). The replacement of the oxygen by a sulfur leads to an increase of the affinity while the function-i.e., inverse agonism-determined by [(35)S]GTPgammaS experiments remains unaffected. Finally, to evaluate the molecular

  合成了一组30个取代的5,5'-二苯基-2-硫代氧杂咪唑啉-4-酮（硫代乙内酰脲）衍生物，并评估了它们对人CB（1）大麻素受体的亲和力。这些化合物衍生自先前描述的大麻素配体5,5'-二苯基咪唑烷-2,4-二酮（乙内酰脲）。用硫取代氧会导致亲和力增加，而[[35] S] GTPgammaS实验所确定的功能（即反向激动作用）仍然不受影响。最后，为了评估可能影响巯基乙内酰脲亲和力的分子参数，对代表性的巯基乙内酰脲和乙内酰脲衍生物进行了分子静电势以及亲脂性计算。总之，5,5'-双-（4-碘苯基）-3-丁基-2-硫代氧杂咪唑啉丁-4-酮（31）和3-烯丙基-5，